Locations
Boston, MA, USA
industry
Biotechnology · Data and Analytics · DeepTech · Design · Health
Size
51-200 employees
Stage
Series B
founded in
2021
Aera Therapeutics is a biotechnology company that uses its proprietary protein nanoparticle (PNP) delivery platform to help genetic medicines reach their full potential. Aera's platform, which is based on endogenous human proteins, is being developed to address the limitations of current delivery technologies and to extend the reach of genetic medicines to different tissues and applications, thereby benefiting more patients across a broader range of disease areas. In addition, Aera's licensed technology includes a therapeutic enzyme platform based on the discovery of novel, compact, and programmable gene-editing enzymes.
Something looks off?